RxDoctor Payments DataLook up a doctor →

John Myers, MD

Retina Specialist · Pensacola, FLNPI 1881661585

Payments from drug & device makers

$152,047in general payments, 2019–2025

Across 289 payments — averaging $526.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$103K
  • US Retina LLC$27K
  • Genentech USA, Inc.$19K
  • Apellis Pharmaceuticals, Inc.$912
  • AbbVie$680
  • Alimera Sciences, Inc.$425
  • plus $1K from 11 others

What the payments were for

  • Speaking & faculty fees$102,87068%
  • Travel & lodging$14,46010%
  • Food & beverage$8,0615%
  • Ownership interest$25,19917%
  • Other$1,4561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,047 in reported general payments places this provider in the 75th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$7,025,323
Medicare patients
1,924
Services billed
62,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost65$32,437
Prednisolone Acetate249$14,741
CombiganBrimonidine Tartrate/Timolol30$11,674
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$7,662
ProlensaBromfenac Sodium16$6,013
Brimonidine Tartrate77$5,392
Bromfenac Sodium27$4,786
Travoprost11$3,427
MoxifloxacinMoxifloxacin Hcl132$3,378
Difluprednate27$3,254
Loteprednol Etabonate11$2,419
Timolol Maleate167$2,144
Latanoprost230$2,047
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha143$1,668
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$1,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$680$44,11295 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$100$8,43227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →